About CRISPR Therapeutics AG - Common Shares (CRSP)
Crispr Therapeutics is a biopharmaceutical company that focuses on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing technology. The company aims to harness the potential of genetic editing to treat various conditions, including genetic disorders, cancer, and autoimmune diseases. Through a combination of innovative research and strategic collaborations, Crispr Therapeutics is dedicated to advancing its pipeline of therapies and ultimately improving patient outcomes and quality of life. Read More
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.
Speaking at a Bank of America fireside chat host
As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant dominated the CF landscape with its groundbreaking CFTR modulators, but today, the narrative has shifted to a broader multi-disease platform. With the successful 2025 launch of [...]
